Richard Haynes

DM, MRCP

Associate Professor

MRC Project Leader Track
MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis

Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he now works on randomized trials and epidemiology (particularly in renal medicine and cardiovascular disease) at CTSU.

Recent publications

Long term outcomes in monoclonal gammopathy of renal significance.
Other

Khera A. et al, (2019), Br J Haematol
Chronic kidney disease, heart failure and neprilysin inhibition.
Journal article

Haynes R. et al, (2019), Nephrol Dial Transplant
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Journal article

Schlackow I. et al, (2019), Kidney Int
Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials.
Journal article

Offer A. et al, (2019), JAMA Netw Open, 2
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.
Other

Herrington WG. et al, (2019), Ann Intern Med, 170

More publications